Navigation Links
New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
Date:1/5/2011

RIDGEFIELD, Conn., Jan. 5, 2011 /PRNewswire/ -- Results of a post-hoc analysis of the RE-LY® trial among patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion, a treatment to convert an abnormal heartbeat back to normal sinus rhythm, were published online on Jan. 3 in Circulation.(1)  Stroke and systemic embolism and major bleeding episodes within 30 days of the cardioversion were the major outcome measures.  The analysis reported that rates of stroke and systemic embolism and major bleeding were low and comparable to warfarin in cardioverted patients receiving Pradaxa® (dabigatran etexilate mesylate) 150mg capsules,(1) an oral anticoagulant recently approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with NVAF.(2)

In RE-LY, a total of 1,983 cardioversions were performed in 1,270 patients, with similar numbers in each treatment group (647 in the dabigatran 110mg* group, 672 in the PRADAXA 150mg group and 664 in the warfarin group).(1)  Rates of stroke and systemic embolism within 30 days of cardioversion were low and did not differ significantly between treatment arms (0.77%, 0.3% and 0.6%, respectively; dabigatran 110mg vs. warfarin, p=0.71; PRADAXA 150mg vs. warfarin, p=0.45),(1) though the RE-LY trial and this subgroup analysis were not powered to demonstrate statistical significance.  Similarly, major bleeding within 30 days of cardioversion was infrequent and comparable between treatment groups (1.7%, 0.6% and 0.6%, respectively).(1)

"Cardioversion is one treatment option for patients with atrial fibrillation and requires anticoagulation both prior to and following treatment in order to reduce the risk of stroke," said Rangadham Nagarakanti, MD, Louisiana State University School of Medicine.  "It's helpful to know that patients on PRADAXA who underwent cardioversion had low rates of stroke and systemic embolism
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New PLATO Sub-Analysis of CABG Patients Presented at ACC
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 In the current outcomes-focused ... upon Health Outcomes Liaison (HOL) staff to serve ... leaders, and other important healthcare decision makers. As ... grows, successful companies will need to understand how ... function. To help organizations identify industry ...
(Date:9/12/2014)... 2014  Pomerantz LLP has filed a class action ... IPXL ) and certain of its officers.  The ... of New Jersey , and docketed ... of all persons or entities who purchased Impax securities ... (the "Class Period").  This class action seeks to recover ...
(Date:9/12/2014)... ViewRay™, a privately held medical device company, ... system, the world,s first and only MRI-guided radiation therapy ... the American Society for Radiation Oncology (ASTRO) being held ... . With ViewRay,s recent announcements of the world,s first ... and the first patient treated at the University of ...
Breaking Medicine Technology:Pharmaceutical Sector Turning to Health Outcomes Liaisons to Help Industry Navigate Payer-Focused Marketplace 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Impax Laboratories, Inc. and Certain Officers - IPXL 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Impax Laboratories, Inc. and Certain Officers - IPXL 3ViewRay to Showcase World's Only MRI-Guided Radiation Therapy System In Clinical Use at Largest Radiation Oncology Meeting 2ViewRay to Showcase World's Only MRI-Guided Radiation Therapy System In Clinical Use at Largest Radiation Oncology Meeting 3
... 2011 Today OncoGenex (NASDAQ: ... an amendment to the approved SPA with the U.S. Food ... the Prostate Cancer SATURN Clinical Trial - a Phase III ... OGX-011/TV-1011, can improve quality of life by reducing cancer pain ...
... Hanger Orthopedic Group, Inc. today announced it ... Chief Operating Officer of its orthotic and prosthetic ... immediately.  Mr. Wilson brings more than 20 years ... of medical/surgical and pharmaceutical products to physician offices, ...
Cached Medicine Technology:OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 2OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 3OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial 4Hanger Orthopedic Group Names Kenneth W. Wilson as President and Chief Operating Officer of Distribution Business Unit, SPS 2Hanger Orthopedic Group Names Kenneth W. Wilson as President and Chief Operating Officer of Distribution Business Unit, SPS 3
(Date:9/14/2014)... NY (PRWEB) September 14, 2014 Transvaginal ... filed in New Jersey, where two separate litigations are ... LLP reports. , According to Case Lists updated ... filed over devices marketed by C.R. Bard Inc., and ... involving cases against C.R. Bard, a total of 1,557 ...
(Date:9/14/2014)... School requires that children read at both near ... screened only for far vision when they enter school. , ... their eyes do not track effectively or focus (team) on ... avoid reading; at worst, they will think there is ... Children who cannot see cannot read. , On November ...
(Date:9/13/2014)... September 13, 2014 Ticket Down ... concert tickets. This beloved pop-rock group that originally formed in ... studio album. Fans of the group had been anticipating a ... If fans were excited yet about the release of their ... 5 has announced a massive worldwide tour beginning in the ...
(Date:9/13/2014)... York (PRWEB) September 13, 2014 Stryker ... of the 2012 Rejuvenate and ABG II Modular-Neck Hip ... underway in New Jersey’s Bergen County Superior Court, Bernstein ... issued by the Court on September 10th, 2,097 cases ... increase of 33 filings since the Court issued its ...
(Date:9/13/2014)... September 13, 2014 Hastings and Hastings, ... over 30 years of dedicated client friendly legal services. ... years of cumulative combined experience, Hastings and Hastings offers ... to clients. Even more impressive is the fact that ... boasts 11 offices located across the entire state of ...
Breaking Medicine News(10 mins):Health News:New Jersey Litigations Continue to Add Ethicon, C.R. Bard Transvaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports 2Health News:New Jersey Litigations Continue to Add Ethicon, C.R. Bard Transvaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports 3Health News:New Jersey Litigations Continue to Add Ethicon, C.R. Bard Transvaginal Mesh Lawsuits, Bernstein Liebhard LLP Reports 4Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Stryker Hip Lawsuit News: Rejuvenate and ABG II Hip Lawsuit Filings Near 2,100 in New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: Rejuvenate and ABG II Hip Lawsuit Filings Near 2,100 in New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Hastings & Hastings Reports Reaching 30 Years Of Dedicated Client Friendly Legal Services 2Health News:Hastings & Hastings Reports Reaching 30 Years Of Dedicated Client Friendly Legal Services 3
... This release is available in German . ... and learning about the warning signs of lymphedema: that,s ... lymphedema, according to the German Institute for Quality and ... about how to protect themselves from this common and ...
... AUGUSTA, Maine, Nov. 6 Building on the ... for small businesses in Maine,the Maine State Chamber ... and Blue Shield have announced further additions to ... January, Chamber,BlueOptions will include eight health plans from ...
... Invisicare Is Put In Place, LAS VEGAS, ... the developers of Invisicare, a patented polymer,delivery system ... of Geert Cauwenbergh, PhD to head its International,Advisory ... expand the demand,for Invisicare in international markets. Dr. ...
... Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Co., Inc., (Amex: ... traditional Chinese medicine ("TCM") based in Chengdu, China,today ... to discuss its,2009 fiscal first quarter at 8:30 ... will be released that day before the market ...
... A steady march toward using,ever-more "patient-friendly" ... proceedings of the 37th Global Congress of ... international professional society for,specialists in minimally invasive ... preserving the highest possible quality of,life for ...
... People With,Diabetes and Their Caregivers, WESTPORT, Conn., Nov. ... laughter, and family, usually accompanied by trays of cookies,cakes, ... some,of the nearly 24 million people in America with ... dLife helped over 100,000 online,visitors survive the season with ...
Cached Medicine News:Health News:How women can improve their quality of life after breast cancer treatment 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 2Health News:Chamber BlueOptions Insurance Adds to its Options and Benefits for 2009 Suite of Insurance Plans Meeting Small Business Needs 3Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 2Health News:Skinvisible Appoints Dr. Geert Cauwenbergh to Its International Advisory Board 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 2Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 3Health News:Hi-Tech Advances the Practice of Minimally Invasive Gynecology at AAGL Global Congress 4Health News:Back By Popular Demand - dLife Holiday Helpline 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
Medicine Products: